Comparative in vitro potency of amoxycillin-clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study

International Journal of Antimicrobial Agents

Volumn 21, Issue 5, 2003, Pages 425-433

  Hoban, D J ^a,c   Bouchillon, S K ^a   Johnson, J L ^a   Zhanel, G G ^a   Butler, D L ^b   Saunders, K A ^b   Miller, L A ^b   Poupard, J A ^b   Baron, Ellen Jo ^d   Sherretta, Annemarie ^e   Thomson, Richard ^f   Low, D ^g   Hoban, Daryl ^h   Church, Diedre ⁱ   Kibsey, Pamela ^j   Gregson, Dan ^k   Hutchinson, James ^l   Weiss, Karl ^m   Kuhn, Magdalena ⁿ   Forward, Kevin ^o   Toye, Baldwin ^p   more..

^a Labs Intl for Microbiology Studies   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Division of Microbiology   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e BRYN MAWR HOSPITAL   (United States)

^f EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h HEALTH SCIENCES CENTRE   (Canada)

ⁱ CALGARY LABORATORY SERVICES   (Canada)

^j VICTORIA GENERAL HOSPITAL   (Canada)

^k ST JOSEPH S HEALTH CENTRE   (Canada)

^l St John's General Hospital   (Canada)

^m MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

ⁿ MONCTON HOSPITAL   (Canada)

^o QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^p UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

Amoxycillin clavulanic acid; Ampicillin; Antimicrobial surveillance; Azithromycin; Cefuroxime; In vitro; North America; Trimethoprim sulphamethoxazole

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; CEFUROXIME; CLAVULANIC ACID; COTRIMOXAZOLE; MACROLIDE; PENICILLIN G;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA; CANADA; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PENICILLIN RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS EPIDERMIDIS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; UNITED STATES;

EID: 0037405875     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00038-4     Document Type: Article

References (13)

1. Ball A.P., Davey P.G., Geddes A.M., Farrell I.D., Brooker G.R. Clavulanic acid and amoxycillin: a clinical, bacteriological tool and pharmacological study. Lancet. 1:1980;620-623.
2. Low D.E., Keller N., Barth A., Jones R.N. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of Enterococci: results from the SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 32:(Suppl. 2):2001;S133-S145.
3. Diekema D.J., Pfaller M.A., Schmitz F.J., Smayevsky J., Bell J., Jones R.N., Beach M. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe and the Western Pacific Region for the SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 32:(Suppl. 2):2001;S114-S132.
4. Gales A.C., Jones R.N., Turnidge J., Rennie R., Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates antimicrobial susceptibility patterns and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 32:(Suppl. 2):2001;S146-S155.
5. Hoban D.J., Doern G.V., Fluit A.C., Roussel-Delvalley M., Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 32:(Suppl. 2):2001;S81-S93.
6. Thornsberry C., Jones M.E., Hickey M.L., Mauriz Y., Kahn J., Sahm D.F. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States, 1997-1999. J. Antimicrob. Chemother. 44:1999;749-759.
7. Butler D.L., Gagnon R.C., Miller L.A., Poupard J.A., Felmingham D., Gruneberg R.N. Differences between the activity of penicillin, amoxycillin and co-amoxyclav against 5252 Streptococcus pneumoniae isolates tested in the Alexander Project, 1992-1996. J. Antimicrob. Chemother. 43:1999;777-782.
8. National Committee for Clinical Laboratory Standards. Approved Standard M7-A4. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Clinical Laboratory Standards, Wayne, PA, 1997.
9. National Committee for Clinical Laboratory Standards. M100-S12. Performance Standards for Antimicrobial Susceptibility Testing: Ninth Informational Supplement. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.
10. Fluit A.C., Jones M.E., Schmitz F.J., Acar J., Gupta R., Verhoef J. Antimicrobial susceptibility and frequency of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin. Infect. Dis. 30:2000;454-460.
11. Jones M.E., Thornsberry C., Sahm D.F. The Surveillance Network™ (TSN™): a powerful weapon in the fight against antibiotic resistance. Clin. Lab. 44:1998;961-963.
12. Hoban D.J., Bouchillon S.K., Karlowsky J.A., Johnson J.L., Butler D.L., Miller L.A., Poupard J.A. A comparative in vitro surveillance study of gemifloxacin activities against 2632 recent Streptococcus pneumoniae isolates from across Europe, North America and South America. Antimicrob. Agents Chemother. 44:2000;3008-3011.
13. Padney A., Kapil A., Sood S., Goel V., Das B., Seth P. In vitro activities of ampicillin-sulbactam and amoxicillin-clavulanic acid against Acinetobacter baumanii. J. Clin. Microbiol. 36:1998;3415-3416.